177Lu-DOTA-TLX591

Phase 2

Telix Pharmaceuticals Ltd (TLX)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

9 competitors in Prostate Cancer

SOPHPrGIS

CADLaglatimagene besadenovec

Phase 3

SNYCabazitaxel XRP6258

Phase 2

4503.TCP-461

Phase 2

BTAIBXCL701 plus Pembrolizumab

Phase 2

View Full Landscape

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

NCT05146973

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

TLX

Telix Pharmaceuticals Ltd

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

177Lu-TLX591Phase 3

Metastatic Castration-resistant Prostate Cancer

68Ga-PSMA-11Phase 3

Biochemical Recurrence of Malignant Neoplasm of Prostate

89Zr-TLX250 PET/CTPhase 3

Clear Cell Renal Cell Carcinoma

Fluciclovine F18Phase 2

Prostate Adenocarcinoma

PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CCPhase 2

Prostate Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts